On August 28, BioNTech announced that after consultation with partner Genentech, it was decided to terminate the phase II clinical trial of the individualized mRNA cancer immunotherapy Autogene cevumeran for adjuvant treatment of colorectal cancer. The decision stemmed from a recent evaluation by the Independent Data Safety Monitoring Committee, which found that there was a numerical difference in overall survival between the trial treatment group and the control group, and it was believed that continuing the trial was unlikely to change the efficacy results.

On August 28, BioNTech announced that after consultation with partner Genentech, it was decided to terminate the phase II clinical trial of the individualized mRNA cancer immunotherapy Autogene cevumeran for adjuvant treatment of colorectal cancer. The decision stemmed from a recent evaluation by the Independent Data Safety Monitoring Committee, which found that there was a numerical difference in overall survival between the trial treatment group and the control group, and it was believed that continuing the trial was unlikely to change the efficacy results.